Business Wire

IKEUCHI

8.1.2024 13:01:28 CET | Business Wire | Press release

Share
7 Benefits of Dry Fog Humidity Control System in SMT Processes | IKEUCHI

H. IKEUCHI & CO., LTD., a Japanese spray nozzles manufacturer, has launched a global campaign to introduce humidity control systems powered by “Dry Fog” technology.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240108276401/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Each individual photo available upon request: IKEUCHI offers humidity control systems using Dry Fog not only preventing static electricity in SMT processes but also significantly slashing operating costs and CO2 emissions.(Photo: Business Wire)

“Dry Fog” is formed out of ultrafine water droplets, each measuring 10 μm or less in diameter, generated by specialized spray nozzles. This fog rapidly evaporates into the air without wetting the objects it touches.

In the realm of surface-mount technology (SMT) processes, effective humidity control is crucial to combat electrostatic discharge (ESD) issues and challenges arising from static electricity and dry air. IKEUCHI's Dry Fog Humidification System emerges as a groundbreaking solution, delivering seven key benefits.

1. ESD Damage Prevention
As electronic components shrink, susceptibility to electrostatic discharge increases. The Dry Fog system ensures a uniform humidity level, preventing the risk of ESD damage.

2. Reduced Pick-and-Place Errors
Maintaining optimal humidity levels minimizes errors in the pick-and-place process caused by components sticking to or popping out from the tape due to static charge, boosting productivity.

3. Consistent Solder Print Quality
Humidity control during solder printing prevents issues like rapid drying or excessive moisture absorption, ensuring consistent solder print quality and product reliability.

4. Airborne Particle Reduction
Humidification curbs airborne particles, reducing defects caused by particle adherence. The Dry Fog system significantly decreases airborne particles with increased humidity.

5. Significant Operating Cost Reduction
Compared to conventional steam humidification, the Dry Fog system slashes operating costs by 68%, resulting in $50,000/year savings and a 70% CO2 emissions reduction.

6. Cooling Cost Reduction
Evaporative cooling of the Dry Fog lowers ambient temperatures, yielding an $18,000/year saving in cooling expenses at an SMT facility.

7. Healthier Work Environment
Beyond manufacturing, the Dry Fog system reduces sick leave by maintaining a relative humidity of 50% or above, leading to fewer sick days during winter.

In conclusion, IKEUCHI's Dry Fog Humidification System is a comprehensive solution addressing crucial aspects of SMT processes, enhancing productivity, reducing costs, and fostering a healthier workplace. This technology offers a transformative approach to humidity control in electronics manufacturing.

Links to Articles: Part 1, Part 2, Part. 3

Network: U.S., Europe, China, Taiwan, Indonesia, Thailand, Japan

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240108276401/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release

Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release

Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye